Molecular pathology of colorectal cancer

被引：0

作者：

Woischke, Christine ^{[1
]}

Michl, Marlies ^{[2
,3
]}

Neumann, Jens ^{[1
,4
]}

机构：

[1] Ludwig Maximilians Univ Munchen, Pathol Inst, Med Fak, Munich, Germany

[2] Ludwig Maximilians Univ Munchen, Klinikum Univ Munchen, Med Klin & Poliklin 3, Munich, Germany

[3] Facharztpraxis Innere Med Hamatol & Onkol Tageskli, Munich, Germany

[4] Ludwig Maximilians Univ Munchen, Pathol Inst, Med Fak, Thalkirchner Str 36, D-80337 Munich, Germany

来源：

PATHOLOGIE | 2023年 / 44卷 / 05期

关键词：

Biomarkers; Liquid biopsy; Precision medicine; Proto-oncogene proteins B-raf; Microsatellite instability; FOLFIRI PLUS CETUXIMAB; KRAS MUTATION ANALYSIS; MICROSATELLITE-INSTABILITY; CLINICAL-PRACTICE; RAS MUTATIONS; BRAF; PROGNOSIS; CHEMOTHERAPY; METAANALYSIS; METASTASES;

D O I：

10.1007/s00292-023-01201-9

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

In recent years, the treatment of colorectal carcinoma has experienced increasing individualization. In addition to RAS and BRAF mutational status that is firmly established in routine diagnostics, new therapeutic options evolved based on MSI and HER2 status as well as primary tumour localization. Offering the best targeted options in therapy requires new evidence-based decision-making algorithms regarding timing and scope of molecular pathological diagnostics in order for patients to receive an optimized therapy according to current treatment guidelines. New targeted therapies, some of which are about to be approved and for which pathology has to provide new molecular pathological biomarkers, will also play an increasingly important role in the future.

引用

页码：279 / 286

页数：8

共 63 条

[1] A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer [J].

Adelstein, Barbara-Ann ;

Dobbins, Timothy A. ;

Harris, Carole A. ;

Marschner, Ian C. ;

Ward, Robyn L. .

EUROPEAN JOURNAL OF CANCER, 2011, 47 (09) :1343-1354

[2]

Ahcene Djaballah Selma, 2022, Am Soc Clin Oncol Educ Book, V42, P1, DOI 10.1200/EDBK_351354

[3] The clinical relevance of gene expression based prognostic signatures in colorectal cancer [J].

Ahluwalia, Pankaj ;

Kolhe, Ravindra ;

Gahlay, Gagandeep K. .

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2021, 1875 (02)

[4] Oncotype DX testing does not affect clinical practice in stage IIa colon cancer [J].

Allar, Benjamin G. ;

Messaris, Evangelos ;

Poylin, Vitaliy Y. ;

Schlechter, Benjamin L. ;

Cataldo, Thomas E. .

MEDICAL ONCOLOGY, 2022, 39 (05)

[5] Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].

Amado, Rafael G. ;

Wolf, Michael ;

Peeters, Marc ;

Van Cutsem, Eric ;

Siena, Salvatore ;

Freeman, Daniel J. ;

Juan, Todd ;

Sikorski, Robert ;

Suggs, Sid ;

Radinsky, Robert ;

Patterson, Scott D. ;

Chang, David D. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634

[6] EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer [J].

Amodio, Vito ;

Yaeger, Rona ;

Arcella, Pamela ;

Cancelliere, Carlotta ;

Lamba, Simona ;

Lorenzato, Annalisa ;

Arena, Sabrina ;

Montone, Monica ;

Mussolin, Benedetta ;

Bian, Yu ;

Whaley, Adele ;

Pinnelli, Marika ;

Murciano-Goroff, Yonina R. ;

Vakiani, Efsevia ;

Valeri, Nicola ;

Liao, Wei-Li ;

Bhalkikar, Anuja ;

Thyparambil, Sheeno ;

Zhao, Hui-Yong ;

de Stanchina, Elisa ;

Marsoni, Silvia ;

Siena, Salvatore ;

Bertotti, Andrea ;

Trusolino, Livio ;

Li, Bob T. ;

Rosen, Neal ;

Di Nicolantonio, Federica ;

Bardelli, Alberto ;

Misale, Sandra .

CANCER DISCOVERY, 2020, 10 (08) :1129-1139

[7] Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials [J].

Arnold, D. ;

Lueza, B. ;

Douillard, J. -Y. ;

Peeters, M. ;

Lenz, H. -J. ;

Venook, A. ;

Heinemann, V. ;

Van Cutsem, E. ;

Pignon, J. -P. ;

Tabernero, J. ;

Cervantes, A. ;

Ciardiello, F. .

ANNALS OF ONCOLOGY, 2017, 28 (08) :1713-1729

[8] RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study [J].

Bachet, J. B. ;

Bouche, O. ;

Taieb, J. ;

Dubreuil, O. ;

Garcia, M. L. ;

Meurisse, A. ;

Normand, C. ;

Gornet, J. M. ;

Artru, P. ;

Louafi, S. ;

Bonnetain, F. ;

Thirot-Bidault, A. ;

Baumgaertner, I ;

Coriat, R. ;

Tougeron, D. ;

Lecomte, T. ;

Mary, F. ;

Aparicio, T. ;

Marthey, L. ;

Taly, V ;

Blons, H. ;

Vernerey, D. ;

Laurent-Puig, P. .

ANNALS OF ONCOLOGY, 2018, 29 (05) :1211-1219

[9]

Baretton G, 2016, PATHOLOGE, V37, P361, DOI 10.1007/s00292-016-0179-3

[10]

Bendardaf R, 2008, ANTICANCER RES, V28, P3865

← 1 2 3 4 5 6 7 →